Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


NECC Crisis Festered in Ambiguity That Reigns Over Compounding

This article was originally published in The Gold Sheet

Executive Summary

As FDA, Congress and the courts stumbled, compounding pharmacies such as NECC took advantage of a gray area of the law. Legislators will get another try; one proposed subjecting such pharmacies to cGMP requirements.


Related Content

Drug Compounder Acquitted Of Murder In Fungal Meningitis Outbreak Case
FDA Inspections Triggered More Pharmacy Recalls in 2015
Risk and Reward: Pharmacy Compounding of Clinical Materials
Compounding: FDA Stepping Up Enforcement With Warning Letters?
Clean Room Lessons from FDA’s Compounding Pharmacy Inspections
Contamination, Mix-Ups Drive Up Drug Recall Totals for 2012
FDA Compounder Inspections May Help Set New Enforcement Standard
A Lesson on Outsourcing: The NECC Fungal Meningitis Outbreak
What FDA Saw at Compounder Behind Fungal Meningitis Outbreak
Supreme Court Reaffirms Least Restrictive Standard For Ad Controls



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts